AVL9 Activators
AVL9 Activators are a group of chemical compounds that enhance the functional activity of AVL9 by influencing specific cellular pathways and processes tightly coupled with AVL9's role in vesicular transport. Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), by increasing at the plasma membrane, can recruit proteins to facilitate membrane trafficking,which AVL9 regulates, thereby enhancing its activity. GTP provides energy for AVL9's transport mechanisms, while calcium ionophore A23187 raises intracellular calcium levels to activate calcium-dependent trafficking processes involving AVL9. Brefeldin A and Monensin disrupt normal protein transport and Golgi function, respectively, which can trigger compensatory cellular responses that increase AVL9 activity to maintain transport efficiency.
N-Ethylmaleimide, by inhibiting vesicle fusion, may necessitate the activation of AVL9 as part of alternative trafficking routes. Forskolin elevates cAMP, leading to PKA activation and subsequent phosphorylation of proteins within AVL9's trafficking pathway. Nocodazole and Cytochalasin D disrupt microtubule and actin polymerization, respectively, which may activate AVL9 as the cell mobilizes compensatory transport mechanisms. Phorbol 12-myristate 13-acetate (PMA) activates PKC, which could enhance AVL9 activity through phosphorylation signaling cascades. Nicotinic acid adenine dinucleotide phosphate (NAADP) elevates calcium from organelles, possibly activating AVL9 by modulating vesicular trafficking. Lastly, Jasplakinolide's stabilization of actin filaments may alter trafficking dynamics, thereby activating AVL9 to adjust vesicle mobility and localization.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
Calcium ionophore A23187 facilitates the increase of intracellular calcium levels. Elevated calcium levels can activate calcium-binding proteins and influence vesicular trafficking pathways. AVL9, involved in vesicular transport, can be activated by the changes in calcium-dependent signaling pathways that modulate vesicle fusion and mobility. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A is a fungal metabolite that blocks protein transport from the endoplasmic reticulum to the Golgi apparatus. AVL9, involved in cellular transport, can be activated as cells attempt to bypass the blockade and maintain transport homeostasis, thereby increasing AVL9-mediated transport activity. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that disrupts Golgi function by altering intracellular pH and ion concentrations. This disruption can stimulate compensatory mechanisms in cellular trafficking, potentially enhancing the activity of AVL9 as part of the cellular response to maintain transport and processing of proteins. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $68.00 $210.00 $780.00 $1880.00 | 19 | |
N-Ethylmaleimide is a sulfhydryl reagent that can inhibit vesicle fusion by modifying SNARE proteins. Its action can stimulate alternative pathways for vesicle trafficking, indirectly enhancing AVL9 activity as the cell adjusts to maintain vesicular transport processes. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels. This elevation can enhance protein kinase A (PKA) activity, which phosphorylates various proteins involved in trafficking. AVL9 could be activated by PKA-mediated phosphorylation or by downstream effects on trafficking pathways that AVL9 is part of. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole is a microtubule-depolymerizing agent that disrupts microtubule dynamics. AVL9, involved in vesicular transport along microtubules, can be activated as cells enhance alternative transport mechanisms to compensate for disrupted microtubule function. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Cytochalasin D inhibits actin polymerization, affecting cytoskeletal dynamics. This can lead to compensatory activation of other cytoskeletal elements or pathways, including those involving AVL9, to maintain vesicular transport and cellular trafficking. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which in turn phosphorylates various proteins involved in cellular signaling and trafficking. AVL9’s activity could be enhanced as part of the PKC-mediated signaling cascade that modulates vesicular transport pathways. | ||||||
NADH disodium salt | 606-68-8 | sc-205762 sc-205762A | 500 mg 1 g | $89.00 $127.00 | 3 | |
NAADP is a potent calcium-mobilizing agent that can release calcium from acidic organelles. The resultant spike in calcium levels can trigger signaling pathways that modulate vesicular trafficking, potentially enhancing the activity of AVL9. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $180.00 $299.00 | 59 | |
Jasplakinolide stabilizes actin filaments and can result in altered cellular trafficking dynamics. AVL9, involved in vesicular transport, can be activated by changes in the actin cytoskeleton that influence vesicle mobility and localization. | ||||||